TFX Teleflex Incorporated

Teleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange

Teleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology Exchange

WAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange. ., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their product or service to supply chain and clinical leaders from Vizient’s provider customers and subject matter experts who serve on their supply councils. Each product or service will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to healthcare delivery or business models.

The VPS Rhythm DLX Device and NaviCurve Stylet are engineered to work together to give Vascular Access Specialists more efficient and predictable PICC placement.

The next-generation VPS Rhythm™ DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity. The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement. This device works in concert with the Arrow™ PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies.

The VPS Rhythm DLX Device eliminates the need for a confirmatory x-ray, helping the clinician insert seamlessly through ultrasound vessel assessment, PICC navigation, to final tip confirmation in the lower third of the superior vena cava.1

Due to the variability of patient vasculature, all PICCs can occasionally have difficulty advancing into the superior vena cava (SVC) on the first attempt. The NaviCurve Stylet features an anatomical curve and flexible tip that are designed to self-orient to patient anatomy for enhanced PICC advancement into the superior vena cava (SVC) for successful insertion.1

“We are very excited to bring our PICCs and Navigation system to the Vizient Innovative Technology Exchange,” says Lisa Kudlacz, President and General Manager, Vascular at Teleflex. “Partnering with healthcare providers to eliminate vascular access related complications is important work, and we are eager to show off the VPS Rhythm DLX Device and updated Arrow PICCs preloaded with the NaviCurve Stylet to demonstrate exactly how it can help enhance care.”

The annual Innovative Technology Exchange is part of Vizient’s that includes product review of supplier-submitted technologies by provider-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rusch, TipTracker, UroLift, VPS Rhythm and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other marks are the property of their respective owners. © 2023 Teleflex Incorporated. All rights reserved. MC-009098

References:

  1. Data on file: D041679 Benchtop Stylet Advancement in a Simulated Use Anatomical Model of NaviCurve™ Product Stylet/PICC Assemblies. Bench testing may not be indicative of clinical performance.

Rx Only

Contact:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

 



EN
15/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthc...

 PRESS RELEASE

Teleflex Reports Second Quarter Financial Results and Full Year 2025 O...

Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch